- Home
- IGMS vs DIBS Comparison
IGMS vs DIBS Comparison
Compare IGMS & DIBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- DIBS
- Stock Information
- Founded
- IGMS 1993
- DIBS 2000
- Country
- IGMS United States
- DIBS United States
- Employees
- IGMS N/A
- DIBS N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- DIBS Catalog/Specialty Distribution
- Sector
- IGMS Health Care
- DIBS Consumer Discretionary
- Exchange
- IGMS Nasdaq
- DIBS Nasdaq
- Market Cap
- IGMS 82.1M
- DIBS 88.1M
- IPO Year
- IGMS 2019
- DIBS 2021
- Fundamental
- Price
- IGMS $1.36
- DIBS $2.85
- Analyst Decision
- IGMS Hold
- DIBS Hold
- Analyst Count
- IGMS 8
- DIBS 1
- Target Price
- IGMS $6.00
- DIBS N/A
- AVG Volume (30 Days)
- IGMS 1.1M
- DIBS 267.2K
- Earning Date
- IGMS 08-13-2025
- DIBS 08-05-2025
- Dividend Yield
- IGMS N/A
- DIBS N/A
- EPS Growth
- IGMS N/A
- DIBS N/A
- EPS
- IGMS N/A
- DIBS N/A
- Revenue
- IGMS $2,681,000.00
- DIBS $88,740,000.00
- Revenue This Year
- IGMS $134.30
- DIBS $3.02
- Revenue Next Year
- IGMS $22.37
- DIBS $6.51
- P/E Ratio
- IGMS N/A
- DIBS N/A
- Revenue Growth
- IGMS 27.36
- DIBS 4.93
- 52 Week Low
- IGMS $0.92
- DIBS $2.30
- 52 Week High
- IGMS $22.50
- DIBS $5.00
- Technical
- Relative Strength Index (RSI)
- IGMS 59.58
- DIBS 55.89
- Support Level
- IGMS $1.12
- DIBS $2.67
- Resistance Level
- IGMS $1.39
- DIBS $2.95
- Average True Range (ATR)
- IGMS 0.08
- DIBS 0.20
- MACD
- IGMS 0.01
- DIBS 0.00
- Stochastic Oscillator
- IGMS 83.87
- DIBS 50.00
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The Company has a single reportable and operating segment that contains one reporting unit, which consists of the Company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.